Please assess the completion status of the following clinical trial:

Trial Title: Trial of NanoPac® in Subjects With Locally Advanced Pancreatic Adenocarcinoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent;~* Age ≥18 years;~* Histologically/cytologically confirmed locally advanced pancreatic adenocarcinoma; at least one lesion with a diameter of at least 1.5 cm but no more than 6 cm as documented via imaging (within 6 weeks of Screening);~* Subject not a candidate for surgery;~* Completion of at least one standard of care IV chemotherapy course for subjects in the dose escalation phase of the study. IV chemotherapy will be initiated prior to first NanoPac injection for subjects in the second and third phases. Hematologic recovery must be confirmed prior to study entry;~* Performance Status (ECOG) 0-1 at study entry;~* Life expectancy of at least 3 months;~* Adequate marrow, liver, and renal function at study entry:~  * ANC ≥ 1.5 x 109/L~ * Hemoglobin ≥ 9.5 grams/dL~ * Platelets ≥ 75 x 109/L~ * Total bilirubin ≤ 1.5x institutional ULN~ * AST/ ALT ≤ 2.5x institutional ULN~ * Creatinine ≤ 1.5x institutional ULN~* Effective contraception if the risk of conception exists.~Exclusion Criteria:~* Thrombotic or embolic events;~* Acute or subacute intestinal occlusion;~* History of inflammatory bowel disease;~* Known hypersensitivity to study drugs;~* Known drug or alcohol abuse;~* Pregnant or breastfeeding women;~* Previous or concurrent history of non-pancreatic malignancy except for non-melanoma skin cancer.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dose Escalation: NanoPac® 6 mg/mL (Type: EXPERIMENTAL): Intratumorally injected NanoPac® at a volume of up to 20% tumor volume
- Dose Escalation: NanoPac® 10 mg/mL (Type: EXPERIMENTAL): Intratumorally injected NanoPac® at a volume of up to 20% tumor volume
- Dose Escalation: NanoPac® 15 mg/mL (Type: EXPERIMENTAL): Intratumorally injected NanoPac® at a volume of up to 20% tumor volume
- Second Phase: NanoPac® at Best Dose (Type: EXPERIMENTAL): Intratumorally injected NanoPac® at a volume of up to 20% tumor volume. The dose administered in the second phase will be determined during the dose escalation phase. Subjects will receive two NanoPac® administrations, with the second injection administered one month after the first injection.
- Third Phase: NanoPac® at Best Dose (Type: EXPERIMENTAL): Intratumorally injected NanoPac® at a volume of up to 20% tumor volume. The dose administered in the third phase will be determined during the dose escalation phase. Subjects will receive four NanoPac® administrations, with the injections administered one month apart.

Based on this trial design, predict the completion outcome and termination type (if applicable).